Dake M D, Miller D C, Semba C P, Mitchell R S, Walker P J, Liddell R P
Department of Radiology, Stanford University School of Medicine, Calif.
N Engl J Med. 1994 Dec 29;331(26):1729-34. doi: 10.1056/NEJM199412293312601.
The usual treatment for thoracic aortic aneurysms is surgical replacement with a prosthetic graft, but the associated morbidity and mortality are considerable. We studied the use of transluminally placed endovascular stent-graft devices as an alternative to surgical repair.
We evaluated the feasibility, safety, and effectiveness of transluminally placed stent-graft to treat descending thoracic aortic aneurysms in 13 patients over a 24-month period. Atherosclerotic, anastomotic, and post-traumatic true or false aneurysms and aortic dissections were treated. The mean diameter of the aneurysms was 6.1 cm (range, 5 to 8). The endovascular stent-grafts were custom-designed for each patient and were constructed of self-expanding stainless-steel stents covered with woven Dacron grafts.
Endovascular placement of the stent-graft prosthesis was successful in all patients. There was complete thrombosis of the thoracic aortic aneurysm surrounding the stent-graft in 12 patients, and partial thrombosis in 1. Two patients initially had small, residual patent proximal tracts into the aneurysm sac, but both tracts thrombosed within two months after the procedure. In four patients, two prostheses were required to bridge the aneurysm adequately. There have been no deaths or instances of paraplegia, stroke, distal embolization, or infection during an average follow-up of 11.6 months. One patient with an extensive chronic aortic dissection required open surgical graft replacement four months later because of progressive dilatation of the arch.
These preliminary results demonstrate that endovascular stent-graft repair is safe in highly selected patients with descending thoracic aortic aneurysms. This new method of treatment will, however, require careful long-term evaluation.
胸主动脉瘤的常规治疗方法是用人工血管进行手术置换,但相关的发病率和死亡率相当高。我们研究了经皮腔内放置血管内支架移植物作为手术修复替代方法的应用。
我们在24个月期间评估了经皮腔内放置支架移植物治疗13例降主动脉瘤的可行性、安全性和有效性。治疗了动脉粥样硬化性、吻合口性和创伤后真性或假性动脉瘤以及主动脉夹层。动脉瘤的平均直径为6.1厘米(范围为5至8厘米)。血管内支架移植物是为每位患者定制设计的,由覆盖有编织涤纶移植物的自膨胀不锈钢支架构成。
所有患者血管内支架移植物的放置均成功。12例患者的支架移植物周围胸主动脉瘤完全血栓形成,1例部分血栓形成。2例患者最初有小的、残留的通向瘤腔的近端通道,但这两个通道在手术后两个月内均血栓形成。4例患者需要两个假体才能充分跨越动脉瘤。在平均11.6个月的随访期间,没有死亡、截瘫、中风、远端栓塞或感染的情况发生。1例患有广泛慢性主动脉夹层的患者在4个月后因主动脉弓逐渐扩张而需要进行开放性手术血管置换。
这些初步结果表明,对于经过严格挑选的降主动脉瘤患者,血管内支架移植物修复是安全的。然而,这种新的治疗方法需要进行仔细的长期评估。